A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

被引：0

作者：

Sen, S. ^{[1
]}

Spira, A. I. ^{[2
]}

Sommerhalder, D. ^{[3
]}

Meric-Bernstam, F. ^{[4
]}

Subbiah, V. ^{[4
]}

Berlin, J. D. ^{[5
]}

Parikh, A. ^{[6
]}

Cecchini, M. ^{[7
]}

Sanborn, R. E. ^{[8
]}

Chablani, P. V. ^{[9
]}

Peoples, G. E. ^{[10
]}

Schurpf, T. ^{[11
]}

Dillon, L. A. ^{[12
]}

Clifton, G. T. ^{[13
]}

Eder, J. P. ^{[14
]}

Tolcher, A. W. ^{[15
]}

机构：

[1] NEXT Oncol TM, Phase 1 Trial Ctr, San Antonio, TX USA

[2] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[3] NEXT Oncol TM, Oncol, San Antonio, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX USA

[5] Vanderbilt Univ, Dept Med, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[6] MGH Massachusetts Gen Hosp, Dept Gastrointestinal Oncol, Boston, MA USA

[7] Yale Univ, Yale Canc Ctr, Oncol, Sch Med, New Haven, CT USA

[8] Earle A Chiles Res Inst, Robert Franz Canc Ctr, Med Oncol, Portland, OR USA

[9] UPMC Hillman Canc Ctr, Med Oncol, Pittsburgh, PA USA

[10] Lumabridge LLC, Dept Surg, San Antonio, TX USA

[11] Parthenon Therapeut, Prot Sci, Cambridge, MA USA

[12] Parthenon Therapeut, Translat Med, Cambridge, MA USA

[13] Parthenon Therapeut, Clin Sci, Boston, MA USA

[14] Parthenon Therapeut, Clin Dev, Boston, MA USA

[15] NEXT Oncol TM, Clin Res Director, San Antonio, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2976

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1079TiP

引用

页码：S649 / S650

页数：2

共 50 条

[1] TRIAL IN PROGRESS: A PHASE 1 FIRST-IN-HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Haber, Tom
Symons, Jessica
Dharmadhikari, Bhushan
Mueller, Thomas
Thakkar, Dipti
Rodon, Jordi Ahnert
Gruber, Joshua
Telli, Melinda
Mita, Monica
Mita, Alain
Patel, Meera
Wang, Daniel
Kim, Joseph
Yadav, Shalini
Sharma, Padmanee
DiMascio, Leah
Rowinsky, Eric
Ingram, Piers
Boyd-Kirkup, Jerome
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A655 - A655
[2] A PHASE 1 FIRST IN HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
DiMascio, Leah
Thakkar, Dipti
Guan, Siyu
Rowinsky, Eric
Rodon, Jordi
Gruber, Joshua
Musher, Benjamin
Kim, Joseph
Mita, Alain
Mita, Monica
Ingram, Piers
Boyd-Kirkup, Jerome
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A498 - A498
[3] First-in-human phase 1 clinical trial of ZM008, a monoclonal IgG1 targeting LLT1, monotherapy and in combination with pembrolizumab in advanced solid tumors
Ghosh, Maloy
Tiwari, Anurag
Dubey, Ashvini Kumar
Bhattacharjee, Sanghamitra
Manjunath, Yogendra
Kashipathi, Shalini
Krishna, Subith
Mandal, Tirtha
Madhusudhan, M. S.
Rodrigues, Golding
CANCER RESEARCH, 2024, 84 (06)
[4] Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFRα in patients with advanced solid malignancies
Youssoufian, H.
Amato, R. J.
Sweeney, C. J.
Chiorean, E. G.
Fox, F.
Katz, T.
Rowinsky, E. K.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5] A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.
Quaratino, Sonia
Sainson, Richard
Thotakura, Anil
Henderson, Simon J.
Pryke, Kerstin
Newton, Anthea
Brennan, Nuala
Oelmann, Elisabeth
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors
Lassen, U.
Schellens, J. H. M.
Siu, L. L.
Jonker, D. J.
Sorensen, M.
Jarutat, T.
Wang, K.
Gehoe, D.
DeMario, M.
Goss, G.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 12 - 12
[7] Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies
Chiorean, E.
Sweeney, C.
Youssoufian, H.
Fox, F.
Katz, T.
Rowinsky, E.
Amato, R.
EJC SUPPLEMENTS, 2008, 6 (12): : 162 - 162
[8] A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Kuenen, Bart
Witteveen, Petronella O.
Ruijter, Rita
Giaccone, Giuseppe
Dontabhaktuni, Aruna
Fox, Floyd
Katz, Terry
Youssoufian, Hagop
Zhu, Junming
Rowinsky, Eric K.
Voest, Emile E.
CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1915 - 1923
[9] A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors
Ahnert, Jordi Rodon
Gruber, Joshua James
Telli, Melinda L.
Mita, Monica M.
Mita, Alain C.
Kim, Joseph W.
Villalona-Calero, Miguel Angel
Patel, Meera
Yadav, Shalini S.
Sharma, Padmanee
Haber, Tom
Lauren, Jessica
Seet, Symons Qihui
Dharmadhikari, Bhushan
Thakkar, Dipti
Kwek, Kon Yew
DiMascio, Leah
Rowinsky, Eric Keith
Ingram, Piers
Boyd-Kirkup, Jerome Douglas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
Geva, Ravit
Voskoboynik, Mark
Dobrenkov, Konstantin
Mayawala, Kapil
Gwo, Jennifer
Wnek, Richard
Chartash, Elliot
Long, Georgina V.
CANCER, 2020, 126 (22) : 4926 - 4935

← 1 2 3 4 5 →